Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lyell Immunopharma (LYEL) FCF Margin (2020 - 2025)

Historic FCF Margin for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to 190926.67%.

  • Lyell Immunopharma's FCF Margin fell 876884300.0% to 190926.67% in Q3 2025 from the same period last year, while for Sep 2025 it was 403743.9%, marking a year-over-year decrease of 1557566000.0%. This contributed to the annual value of 266980.33% for FY2024, which is 1389957100.0% down from last year.
  • As of Q3 2025, Lyell Immunopharma's FCF Margin stood at 190926.67%, which was down 876884300.0% from 432825.0% recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's FCF Margin ranged from a high of 92.69% in Q4 2022 and a low of 1407866.67% during Q1 2024
  • In the last 5 years, Lyell Immunopharma's FCF Margin had a median value of 148496.3% in 2023 and averaged 298857.46%.
  • As far as peak fluctuations go, Lyell Immunopharma's FCF Margin soared by 2000000000bps in 2023, and later crashed by 2000000000bps in 2024.
  • Quarter analysis of 5 years shows Lyell Immunopharma's FCF Margin stood at 1540.79% in 2021, then surged by 94bps to 92.69% in 2022, then crashed by -337336bps to 312769.23% in 2023, then tumbled by -37bps to 429872.73% in 2024, then surged by 56bps to 190926.67% in 2025.
  • Its FCF Margin was 190926.67% in Q3 2025, compared to 432825.0% in Q2 2025 and 785485.71% in Q1 2025.